Meeting
2021 ASCO Annual Meeting
Time intervals between U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) new cancer therapy approvals.
Authors
Mark Lythgoe
Imperial College London, London, United Kingdom
Mark Lythgoe , Jonathan Krell , Jeremy Lyle Warner , Aakash Desai , Ali Raza Khaki
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Care Delivery and Regulatory Policy
Track
Care Delivery and Quality Care
Sub Track
Health and Regulatory Policy
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 1575)
DOI
10.1200/JCO.2021.39.15_suppl.1575
Abstract #
1575
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Mind the gap: Estimating the opportunity lost due to the gap between FDA and EMA cancer drug approvals.
First Author: Samantha Gage
Poster
2024 ASCO Genitourinary Cancers Symposium
Regulatory approvals for genitourinary (GU) cancer by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) over 20 years (2003-2023).
First Author: Sanjay Khanna
Poster
2022 ASCO Annual Meeting
Feasibility of an explainable AI-based therapeutic recommendation-tool utilizing tumor gene expression profiles in advanced and refractory solid tumors.
First Author: Ouissam Al Jarroudi
Poster
2020 ASCO Virtual Scientific Program
Factors associated with change in the magnitude of clinical benefit of anti-cancer drugs in the post-marketing period.
First Author: Aida Bujosa Rodríguez